ZNF750 Knockout cell line (KYSE-30)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

ZNF83 (zinc finger protein 83) encodes a protein predicted to function as a DNA-binding transcription factor specific to RNA polymerase II and its cis-regulatory DNA sequences. It is predicted to participate in the regulation of RNA polymerase II-mediated transcription and to localize to the nucleus. These annotations suggest a potential role in controlling gene expression, although its specific target genes and biological functions are not established in the supplied information.

KYSE-30 is a human esophageal squamous cell carcinoma cell line established from a well-differentiated invasive tumor of the middle thoracic esophagus from a 64-year-old male patient before treatment. The cell line was derived from tumor cells propagated through heterotransplantation in athymic mice. KYSE-30 carries genetic alterations including mutations in TP53, CDKN2A, and HRAS, along with amplification of oncogenes such as c-erb B, MYC, and cyclin D1. The cells are widely used as a model for studying esophageal squamous cell carcinoma biology, oncogenic signaling, tumor progression, and therapeutic responses.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.